Format

Send to

Choose Destination
Am J Nucl Med Mol Imaging. 2015 Jun 15;5(4):333-47. eCollection 2015.

Biodistribution and pharmacokinetics of recombinant α1-microglobulin and its potential use in radioprotection of kidneys.

Author information

1
Department of Clinical Sciences in Lund, Section of Medical Radiation Physics, Lund University Lund, Sweden.
2
Lund University Bioimaging Center, Lund University Lund, Sweden.
3
Department of Clinical Sciences in Lund, Section for Infection Medicine, Lund University Lund, Sweden.
4
Imagene AB Lund, Sweden.
5
Department of Clinical Sciences in Lund, Section of Medical Radiation Physics, Lund University Lund, Sweden ; Lund University Bioimaging Center, Lund University Lund, Sweden.

Abstract

Peptide-receptor radionuclide therapy (PRRT) is a systemically administrated molecular targeted radiation therapy for treatment of neuroendocrine tumors. Fifteen years of clinical use show that renal toxicity, due to glomerular filtration of the peptides followed by local generation of highly reactive free radicals, is the main side-effect that limits the maximum activity that can be administrated for efficient therapy. α1-microglobulin (A1M) is an endogenous radical scavenger shown to prevent radiation-induced in vitro cell damage and protect non-irradiated surrounding cells. An important feature of A1M is that, following distribution to the blood, it is equilibrated to the extravascular compartments and filtrated in the kidneys. Aiming at developing renal protection against toxic side-effects of PRRT, we have characterized the pharmacokinetics and biodistribution of intravenously (i.v.) injected (125)I- and non-labelled recombinant human A1M and the (111)In- and fluorescence-labelled somatostatin analogue octreotide. Both molecules were predominantly localized to the kidneys, displaying a prevailing distribution in the cortex. A maximum of 76% of the injected A1M and 46% of the injected octreotide were present per gram kidney tissue at 10 to 20 minutes, respectively, after i.v. injection. Immunohistochemistry and fluorescence microscopy revealed a dominating co-existence of the two substances in proximal tubules, with a cellular co-localization in the epithelial cells. Importantly, analysis of kidney extracts displayed an intact, full-length A1M at least up to 60 minutes post-injection (p.i.). In summary, the results show a highly similar pharmacokinetics and biodistribution of A1M and octreotide, thus enabling the use of A1M to protect the kidneys tissue during PRRT.

KEYWORDS:

A1M; antioxidation; glomerulus; kidney; octreotide; oxidative stress; prrt; radioprotection; tubule

PMID:
26269772
PMCID:
PMC4529588

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center